Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Multi-marker Analysis Of Circulating Tumor Cells In Localized Intermediate/high-risk And Metastatic Prostate Cancer.
  1. Home
  3. Multi-marker Analysis Of Circulating Tumor Cells In Localized Intermediate/high-risk And Metastatic Prostate Cancer.

Related Experiment Video

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Multi-marker analysis of circulating tumor cells in localized intermediate/high-risk and metastatic prostate cancer.

Eva Welsch1, Lilli Bonstingl2,3, Barbara Holzer1

  • 1Molecular Oncology Group, Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Waehringer Guertel 18-20, Vienna, 1090, Austria.

Clinical & Experimental Metastasis
|September 21, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Circulating tumor cells (CTCs) show high detection rates in early and metastatic prostate cancer (PrC). CTC analysis, especially with PSMA, aids in diagnosing patients for targeted therapies and monitoring treatment response.

Keywords:
Circulating tumor cellsGene expressionLiquid biopsyParsortixProstate cancerqPCR

More Related Videos

An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.6K

Related Experiment Videos

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K
An Orthotopic Murine Model of Human Prostate Cancer Metastasis
06:48

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

35.1K
Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment
05:17

Micromanipulation of Circulating Tumor Cells for Downstream Molecular Analysis and Metastatic Potential Assessment

Published on: May 14, 2019

8.6K

Area of Science:

  • Oncology
  • Molecular Diagnostics
  • Prostate Cancer Research

Background:

  • Circulating tumor cells (CTCs) are established prognostic markers in metastatic prostate cancer (PrC).
  • Their role in localized high-risk PrC remains under-investigated.
  • Early detection and monitoring are crucial for improving patient outcomes.

Purpose of the Study:

  • To evaluate the utility of CTC detection in early and metastatic prostate cancer.
  • To assess CTCs as prognostic markers in localized high-risk PrC.
  • To validate CTC analysis for patient stratification and treatment selection.

Main Methods:

  • Peripheral blood samples collected from early (n=15) and metastatic (n=23) PrC patients.
  • CTCs enriched using microfluidic Parsortix technology.
  • CTC markers quantified via qPCR and RNA in-situ hybridization (ISH); statistical analysis performed using McNemar, Fisher Exact, and log-rank tests.

    • Main Results:

    • High CTC positivity rates observed: 66.7% in early PrC and 87.0% in metastatic PrC at baseline.
    • qPCR and RNA ISH showed high concordance.
    • In metastatic PrC, PSA and PSMA were prognostic for shorter overall survival; early PrC showed increased CTC markers post-radiotherapy and decreased markers during follow-up.

    Conclusions:

    • CTC analysis using qPCR marker panels achieves high detection rates in early PrC.
    • RNA ISH confirms CTC markers at the single-cell level.
    • PSMA-based CTC analysis can aid in screening patients for PSMA-targeted PET-CT or therapies.